Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer

• Main Authors: L. M. Rapoport, Yu. L. Demidko
• Format: Article
• Language: Russian
• Published: ABV-press 2014-12-01
• Series: Andrologiâ i Genitalʹnaâ Hirurgiâ
• Subjects: prostate cancer; synthetic gonadotropin-releasing hormone agonists; buserelin depot
• Online Access: https://agx.abvpress.ru/jour/article/view/110

Buserelin is one of the first synthetic gonadotropin-releasing hormone agonists. The R.M. Fronshtein Clinic of Urology, I.M. Sechenov First Moscow State Medical University, has experience in using Buserelin depot in 32 patients with metastatic prostate cancer. The results of using Buserelin depot for 12 months are described. There was a significant reduction in prostate-specific antigen levels in the entire group.Twenty-seven (84.4 %) patients could achieve tumor stabilization. Twenty (62.5 %) of the 32 patients treated with Buserelin depot at the Clinic of Urology showed decreased residual urine; 9 (28.1%) had no changes and 3 (9.4 %) displayed increased residual urine. The administration of the drug caused significant bone pain relief in 76.5 % of the cases.All the Buserelin depot-treated patients satisfactorily tolerated the given treatment. There was either concomitant disease progression or treatment discontinuation in none of the cases. Thus, Buserelin depot proved to be an effective drug with a good safety profile.